Research Insight
University of Rochester Spearheads FDA Initiative to Speed Development...
Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications ā opioids and...
Research Insight
Phase II Study with Ocrelizumab Shows Significant Reduction in...
Genentech, Inc., a member of the Roche Group, and Biogen Idec announced 24-week results1 from a phase II study of ocrelizumab in patients with relapsing-remitting...
Research Insight
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with...
New findings from the longest assessment of any MS-specific treatment show that patients treated earlier with BetaferonĀ® (interferon beta-1b) had a 39.3% relative reduced risk...
Research Insight
Sanofi-aventis announced the results from the two year phase...
Sanofi-aventis announced the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing...
Research Insight
Novartis Phase III study of AfinitorĀ® plus SandostatinĀ® LARĀ®...
A Novartis Phase III study of AfinitorĀ® (everolimus) tablets in combination with SandostatinĀ® LARĀ®Ā (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or...
Research Insight
Afatinib (BIBW 2992*) triples progression free survival in phase...
Boehringer Ingelheim announced today promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35 th European Society...
Research Insight
The GRACE study has significant implications for inclusion of...
Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.